

EKF Diagnostics Holdings plc
("EKF" or the "Company")

Appointment of CEO

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces the appointment of Gavin Jones as Chief Executive Officer and to the EKF Board, with immediate effect. Gavin previously served as Chief Product Officer at EKF and has extensive industry experience in Analytical Chemistry and Diagnostics. Julian Baines will remain as Executive Chair for the foreseeable future.

In his role as Chief Product Officer, Gavin led the Product Management, R&D, Marketing and Regulatory departments, bringing new and updated products to market, delivering on enhanced connectivity solutions and user-friendly design to meet evolving customer needs. Before joining EKF in 2013, Gavin held a Product Management role at Biotage AB and analyst positions at PCI (then trading as Penn Pharma) and the Forensic Science Service, initially starting out in the laboratory but quickly transitioning to product strategy and innovation. His expertise spans commercial strategy, business development, and product lifecycle management, contributing to significant growth in global healthcare markets.

Gavin holds a BSc (Hons) Forensic and Biomolecular Science degree from Liverpool John Moores University and has a track record of driving product innovation and operational excellence. Gavin is committed to expanding EKF's point-of-care solutions and strengthening its market presence in Life Sciences.



Julian Baines, Executive Chair of EKF, commented: *"I'm delighted that Gavin Jones is taking on the role as Chief Executive Officer and joining the Board. Gavin has over twenty years of experience in Point-of-Care and Life Sciences and has been instrumental in driving the commercial success of many of our products. Many shareholders have met Gavin over the last year or so as he's become more and more involved in the senior leadership team. Gavin has ambitious plans for delivering sustainable growth and unlocking the unrealised potential that our core products and service hold. We have an exciting opportunity to increase our commercial investment to drive organic growth and I'm delighted that Gavin will lead that process."*

Additional Disclosures Required under the AIM Rules for Companies

Gavin Joseph Jones (aged 44) holds no shares in the Company and has held no directorship or partnerships in the past five years.

Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

EKF Diagnostics Holdings plc
Julian Baines, Executive Chair

www.ekfdiagnostics.com
via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker)
Phil Davies / Oliver Platts

Tel: +44 (0)20 7496 3000

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654



About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAPPUQGWUPAPPC